Redx Pharma PLC (AIM: REDX) announced that its primary asset, RXC007, is successfully moving through phase IIa testing, with anticipated results from the idiopathic pulmonary fibrosis research due in the
Redx Pharma plc (AIM:REDX) Collaboration with the Garvan Institute
Redx Announces Collaboration with the Garvan Institute of Medical Research
Redx Pharma plc (REDX.L) Out licensing agreement with AstraZeneca
Lisa Anson, Chief Executive Officer of Redx Pharma, commented : “We are excited by the potential of porcupine inhibition as a novel approach to tackling fibrotic-associated diseases where there is